DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Recombinant Lispro Insulin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
Recombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY 243 million in 2017.
The only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals. By sales value, the market share of Lilly's Recombinant Lispro Insulin exceeded 98% in 2017 but is declining slowly. Optimistic about China's Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin.
For example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R). It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.
It is expected that as the number of diabetic patients continues to increase, China's Recombinant Lispro Insulin market will still have some growth potential.
Topics Covered:
- Situation of diabetes and overview of the antidiabetic drug market in China
- Market size of Recombinant Lispro Insulin in China
- Major Recombinant Lispro Insulin manufacturers in China
- Prices of Recombinant Lispro Insulin in China
- Major factors affecting the development of China's Recombinant Lispro Insulin market
- Prospect of China's Recombinant Lispro Insulin market
Companies Mentioned
- Lilly
- Gan & Lee Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/6bn2qc/investigation?w=4
